Loading clinical trials...
Loading clinical trials...
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes
The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 when administered alone or in combination with glucagon-like peptide 1 (GLP-1) receptor agonist (RA) in participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to approximately 16 weeks excluding the screening period for each participant and include up to 17 visits.
Age
20 - 75 years
Sex
ALL
Healthy Volunteers
No
Pinnacle Research Group, LLC
Anniston, Alabama, United States
CenExel ACT
Anaheim, California, United States
Qps-Mra, Llc
South Miami, Florida, United States
Atlanta Center of Medical Research
Atlanta, Georgia, United States
CenExel-HRI
Berlin, New Jersey, United States
Start Date
June 2, 2022
Primary Completion Date
November 22, 2023
Completion Date
November 22, 2023
Last Updated
January 11, 2024
94
ACTUAL participants
LY3457263
DRUG
Placebo
DRUG
Dulaglutide
DRUG
Lead Sponsor
Eli Lilly and Company
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062